Bradley Foster & Sargent Inc. CT Sells 125 Shares of Agilent Technologies, Inc. (NYSE:A)

Bradley Foster & Sargent Inc. CT decreased its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 5.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,322 shares of the medical research company’s stock after selling 125 shares during the period. Bradley Foster & Sargent Inc. CT’s holdings in Agilent Technologies were worth $312,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in A. CKW Financial Group boosted its position in shares of Agilent Technologies by 114.9% during the 4th quarter. CKW Financial Group now owns 187 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 100 shares in the last quarter. Global X Japan Co. Ltd. boosted its holdings in Agilent Technologies by 161.1% in the fourth quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company’s stock worth $25,000 after acquiring an additional 116 shares in the last quarter. Ashton Thomas Securities LLC bought a new position in Agilent Technologies in the third quarter worth approximately $31,000. Fortitude Family Office LLC boosted its holdings in Agilent Technologies by 68.3% in the third quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company’s stock worth $35,000 after acquiring an additional 95 shares in the last quarter. Finally, Hanson & Doremus Investment Management boosted its holdings in Agilent Technologies by 66.5% in the fourth quarter. Hanson & Doremus Investment Management now owns 263 shares of the medical research company’s stock worth $35,000 after acquiring an additional 105 shares in the last quarter.

Insider Activity at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,911 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total transaction of $286,650.00. Following the completion of the transaction, the chief executive officer now directly owns 39,652 shares of the company’s stock, valued at approximately $5,947,800. This represents a 4.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on A. StockNews.com upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, December 24th. Wells Fargo & Company cut their price target on Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating on the stock in a report on Monday, December 9th. JPMorgan Chase & Co. cut their price target on Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating on the stock in a report on Tuesday, November 26th. Bank of America cut their price target on Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Finally, Barclays raised Agilent Technologies from an “underweight” rating to an “equal weight” rating and increased their price objective for the stock from $135.00 to $145.00 in a research note on Monday, February 10th. Seven research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Agilent Technologies presently has a consensus rating of “Moderate Buy” and an average price target of $144.38.

Agilent Technologies Stock Performance

Shares of A opened at $135.33 on Monday. The company has a current ratio of 2.09, a quick ratio of 1.58 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $38.61 billion, a price-to-earnings ratio of 30.62, a PEG ratio of 3.67 and a beta of 1.07. The stock has a 50 day moving average of $140.97 and a 200 day moving average of $139.34. Agilent Technologies, Inc. has a 12 month low of $124.16 and a 12 month high of $155.35.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Monday, November 25th. The medical research company reported $1.46 EPS for the quarter, beating analysts’ consensus estimates of $1.41 by $0.05. The company had revenue of $1.70 billion during the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a return on equity of 25.43% and a net margin of 19.80%. Agilent Technologies’s revenue was up .8% on a year-over-year basis. During the same period last year, the business posted $1.38 earnings per share. As a group, sell-side analysts forecast that Agilent Technologies, Inc. will post 5.56 earnings per share for the current year.

Agilent Technologies Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st will be given a dividend of $0.248 per share. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.73%. The ex-dividend date is Tuesday, April 1st. Agilent Technologies’s payout ratio is 22.40%.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.